Acromegaly
MONDO:0019933Acromegaly is an acquired disorder related to excessive production of growth hormone (GH) and characterized by progressive somatic disfigurement (mainly involving the face and extremities) and systemic manifestations.
Also known as: Growth hormone excess, pituitary giant, somatotroph adenoma
33 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
New study tracks Octreotide's Real-World impact on acromegaly over two years
Disease control Recruiting nowThis study follows 200 people with acromegaly who are using octreotide subcutaneous depot, a medication that helps control hormone levels. Researchers will monitor safety and effectiveness for up to two years in everyday clinical practice, not a controlled lab setting. The goal i…
Sponsor: Camurus AB • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New shot every 3 months could ease acromegaly treatment
Disease control Recruiting nowThis phase 3 trial tests a new long-acting version of the drug octreotide (Debio 4126) for people with acromegaly, a condition caused by too much growth hormone. The drug is given as a shot every 12 weeks, instead of the usual monthly injections. The study will compare it to a pl…
Phase: PHASE3 • Sponsor: Debiopharm International SA • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo aims to tame acromegaly hormone levels
Disease control Recruiting nowThis phase 2 trial tests whether adding ALXN2420 (a growth hormone blocker) to standard acromegaly treatment can lower IGF-1 levels more than placebo. About 60 adults with acromegaly who are already on a stable dose of somatostatin analogs will receive either ALXN2420 or placebo …
Phase: PHASE2 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug MAR002 takes first step toward treating acromegaly
Disease control Recruiting nowThis Phase 1 trial tests the safety of a new drug called MAR002 in 45 healthy men. Participants receive either MAR002 or a placebo by injection. The goal is to see if it's safe and how the body processes it, before testing it in people with acromegaly.
Phase: PHASE1 • Sponsor: Marea Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Can a newer drug prevent spine fractures in acromegaly patients?
Disease control Recruiting nowThis study looks at whether the drug Pasireotide LAR can reduce the risk of spine fractures in people with acromegaly better than another drug, Pegvisomant. Acromegaly is a condition where too much growth hormone weakens bones, leading to painful fractures. Researchers will follo…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Disease control
Last updated Jun 26, 2026 18:12 UTC
-
New PET scan aims to spot tiny brain tumors that standard MRI misses
Diagnosis Recruiting nowThis early study tests a special PET/MRI scan using a radioactive tracer called FET to find small pituitary tumors that don't show up on regular MRI. The goal is to improve detection of these hormone-producing tumors in 5 adults with confirmed biochemical disease. If the scan wor…
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Jun 27, 2026 11:00 UTC
-
NIH launches major study to unravel hormone mysteries
Knowledge-focused Recruiting nowThis study at the National Institutes of Health is looking at 1,000 adults with known or suspected hormone gland (endocrine) disorders. The goal is to better understand these conditions and help train doctors. Participants may receive tests, treatments, or surgery as part of thei…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Massive study aims to unlock genetic secrets of childhood hormone disorders
Knowledge-focused Recruiting nowThis study enrolls up to 15,000 children with known or suspected endocrine or metabolic disorders, along with their family members. Researchers will collect medical records, blood, saliva, and other samples to identify genetic changes linked to these conditions. The goal is to be…
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Scientists hunt for genetic clues behind childhood pituitary tumors
Knowledge-focused Recruiting nowThis study aims to uncover the genetic causes of pituitary and hypothalamic tumors in children. Researchers will collect blood and tumor samples from up to 2,000 participants to analyze DNA and look for inherited patterns. The study also trains doctors and tests new MRI technique…
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Scientists hunt for hidden genes behind pituitary tumors
Knowledge-focused Recruiting nowThis study aims to find new genes that cause pituitary tumors, including those that lead to acromegaly (gigantism) and prolactinomas. Researchers will collect blood and tissue samples from up to 10,000 people with these tumors and their family members. By analyzing DNA, they hope…
Sponsor: Barts & The London NHS Trust • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Scientists launch major study to unravel hormone disorders
Knowledge-focused Recruiting nowThis study enrolls adults with known or suspected endocrine (hormone gland) disorders, such as diabetes or thyroid disease, to help researchers learn more about these conditions. Participants will undergo medical exams, blood and imaging tests, and possibly genetic testing. The m…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
Can a simple questionnaire predict who will follow their treatment?
Knowledge-focused Recruiting nowThis study is testing a tool called B-COMPASS that uses a 22-question survey to predict whether people will follow their prescribed treatments. Researchers will enroll 3100 adults with cardiovascular, endocrine, immune, nerve, cancer, or rare diseases across Europe. The goal is t…
Phase: NA • Sponsor: Technical University of Madrid • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC